Website intended for a NZ health professional readership
Writing on The Conversation, Chris Hammond and Katie Williams of King’s College, London, consider the potential factors behind a global increase in myopia
1. Morgan I, Ohno-Matsui K, Saw SM. Myopia. Lancet 2012;379(9827):1739–48.
2. Williams KM, Bertelsen G, Cumberland P, et al. Increasing prevalence of myopia in Europe and the impact of education. Ophathalmology 2015;122(7):1489–97.
3. Huang HM, Chang DS, Wu PC. The association between near work activities and myopia in children–a systematic review and meta-analysis. PLoS One 2015;10(10):e0140419.
4. Ip JM, Rose KA, Morgan IG, et al. Myopia and the urban environment: Findings in a sample of 12-year-old Australian school children. Invest Opth Vis Sci 2008;49:3858–63.
5. Rose KA. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology 2008;115(8):1279–85.
6. Mutti DO. Has near work's star fallen? Optom Vis Sci 2009;86(2):76–78.
7. Sherwin JC, Reacher MH, Keogh RH, et al. The association between time spent outdoors and myopia in children and adolescents. Ophathlmology 2012;119(10):2141–51.
8. He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia among children in China: A randomized clinical trial. JAMA 2015;314(11):1142–48.
9. Fan Q, Guo X, Tideman JW, et al. Childhood gene-environment interactions and age-dependent effects of genetic variants associated with refractive error and myopia: The CREAM Consortium. Sci Rep 2016;6:25853.
10. Fan Q, Verhoeven VJ, Wojciechowski R, et al. Meta-analysis of gene–environment-wide association scans accounting for education level identifies additional loci for refractive error. Nat Commun 2016;7:11008.
11. Williams KM, Venturini C, Yonova EH, et al. Evidence for shared genetic factors between myopia and intelligence in the Twins Early Development Study (TEDS). Invest Opth Vis Sci 2015;56:907.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
